NCT02005744

A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function

A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function Compared With Normal Hepatic Function

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 64 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate pharmacokinetics of CKD-501 in patients with impaired hepatic function compared with normal hepatic function.

Detailed description

A Phase 1, Non-randomized, Open, Parallel-Group study.

Conditions

• Liver Dysfunction

Interventions

Type	Name	Description
DRUG	CKD-501	CKD-501 0.5mg, PO(per oral), once

Timeline

• Start date: 2014-03-01
• Primary completion: 2016-02-01
• Completion: 2016-02-01
• First posted: 2013-12-09
• Last updated: 2016-07-04

Locations

1 site across 1 country: South Korea